Livagen
Also known as Lys-Glu-Asp-Ala, KEDA
A tetrapeptide bioregulator (Lys-Glu-Asp-Ala) developed by Khavinson that modulates chromatin structure. Studies in elderly subjects (75-88 years) showed activation of ribosomal genes.
Regulatory Pathway
Dosing Protocol
Typical Dose
10-20 mg daily
Frequency
Once or twice daily
Duration
10-30 day cycles
Timing & Administration
Administer via Oral capsules or sublingual. Frequency: Once or twice daily.
Popular Uses
Mechanism of Action
Penetrates the cell nucleus and directly influences DNA transcription by decondensing chromatin structure. Activates ribosomal genes, modulates heterochromatin organization, and affects enkephalin-degrading enzyme activity.
Research Summary
Evidence level: animal studies. Clinical status: Preclinical research; approved in Russia as supplement.
Side Effects & Safety
Important Warnings
- Not FDA approved
References
No references available.
Related Peptides
Browse all →A tripeptide bioregulator targeting liver and gastrointestinal tissue, derived from liver tissue extracts. Modulates gene expression related to detoxification, antioxidant defense, and cellular repair.
View profileA tetrapeptide bioregulator (Ala-Glu-Asp-Pro) derived from cerebral cortex extracts. Studied for neuroprotection, neural differentiation, and cognitive support.
View profileA tripeptide bioregulator targeting vascular tissue that promotes restoration of blood vessel tissues and normalization of vascular function.
View profile